Tetra Radar · FDA Approvals · Decision date
KRESLADI: FDA decision date
Rocket Pharmaceuticals Inc (RCKT) · 28 March 2026
KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date.
Source: 8-K of 26 February 2026
The FDA approved it on 26 March 2026.
The FDA approved KRESLADI for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen (HLA)-matched sibling donor for allogeneic hematopoietic stem cell transplant.
Rocket Pharmaceuticals Inc on Tetra Radar
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.